Zimmer Biomet Wins Price Purpose Elevate At Roth

Roth Capital Markets analyst Jason Wittes raised his value aim on Zimmer Biomet Holdings (Zimmer Biomet Holdings Stock Quote, Chart, Data, Analysts, Financials NYSE:ZBH) to $135 and maintained a “Buy” rating in a July 15 report, citing the company’s acquisition of Monogram Utilized sciences as a key switch to close a distinct segment in its robotics capabilities.

Wittes talked about the deal strengthens Zimmer Biomet’s core large joint enterprise and better positions it to compete with Stryker’s MAKO robotic system. He added that the present acquisition of Paragon 28 moreover alerts a shift in direction of higher-growth options, similar to the path Stryker began twenty years prior to now. The model new value aim relies on 16 events Roth’s 2026 EPS estimate of $8.34, up from the sooner $115 aim primarily based totally on 14–15 events the 2025 estimate of $7.90.

Zimmer Biomet, primarily based in Warsaw, Indiana, develops medical know-how for joint substitute, sports activities actions medicine, trauma care, and bone reconstruction. Its merchandise embrace knee and hip implants, surgical devices, robotic packages, and bone cement. The company serves surgeons, hospitals, and healthcare suppliers globally. Based mostly in 1927, it adopted its current title in 2015.

The Monogram deal consists of an preliminary $177-million in cash, or $4.04 per share, roughly in step with Roth’s standalone aim for Monogram. It moreover contains a non-tradable contingent value correct (CVR) worth as a lot as $12.37 per share, doubtlessly elevating the total value to $750-million.

“We picked up safety of Monogram (MGRM–Buy) this earlier December, believing it was one among many few rising robotics platforms that will doubtlessly downside SYK’s dominance in orthopedic robotics with MAKO,” Wittes talked about.

He pointed to Monogram’s mBôs platform, which makes use of AI to info precise bone chopping and personalization—two areas Roth sees as central to MAKO’s administration, which they estimate accounts for about 80% of robotic knee surgical procedures. Zimmer Biomet’s private ROSA platform, launched in 2020, now has over 2,000 installations.

“Nonetheless, we see ROSA as severely lacking in every preparation and personalization, and a major motive for ZBH share stagnation in large joints,” Wittes talked about. “Whereas ZBH was slowly catching up on enhancing ROSA’s potential to ship custom-made surgical process, along with the present launch of CT-based planning (facilitating a additional kinematic methodology to knee surgical process), SYK’s strong IP portfolio positioned a significant barrier on ROSA’s hand-based chopping potential.”

Wittes talked about plenty of that IP services on the utilization of haptics and recommendations to info a surgeon’s hand.

“mBôs takes a very automated methodology to chopping, eliminating the need for haptics, which not solely will get spherical SYK’s IP fortress spherical hand-based chopping (which so far has been a limiting problem for competing robotic designs), however as well as creates a strong IP fortress spherical completely autonomous chopping,” he talked about. “In addition to, mBôs makes use of superior AI planning, which allows for inter-operative adjustments to streamline personalization, which we see as rivalling MAKO’s current capabilities.”

As quickly because the deal closes, Zimmer Biomet talked about it expects to show into the first orthopedic agency to provide a very autonomous surgical robotic.

“Monogram’s know-how is a major leap forward, demonstrating our dedication to becoming the boldest and broadest innovator in surgical robotics and navigation,” talked about Ivan Tornos, Chairman, President and CEO of Zimmer Biomet, in a press launch saying the acquisition. “Upon closing, our customer-centric portfolio will embody basically probably the most full and versatile know-how ecosystem to help the varied preferences of an infinite array of surgeons, now and into the long term. With Monogram’s proprietary know-how, Zimmer Biomet has the potential to show into the first agency to ship completely autonomous capabilities and redefine every the standard of care and the way in which ahead for orthopedic surgical process.”

-30-